However, these genetic alterations are not common enough to fully explain the frequency of increased YAP/TAZ expression and nuclear localization, which suggests that other cancer-associated pathways can promote inappropriate YAP/TAZ activity. The gene discussed is WWTR1; the disease is cancer.